Organon (OGN) Other Non-Current Assets (2020 - 2025)
Organon (OGN) recorded quarterly Other Non-Current Assets of $8.0 million in Q4 2025, down 93.33% quarter-over-quarter from $120.0 million in Q1 2021.
Organon (OGN) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Organon's Other Non-Current Assets history runs 3 years deep, the most recent figure standing at $8.0 million for Q4 2025.
- In Q4 2025, Other Non-Current Assets changed N/A year-over-year to $8.0 million; the TTM figure through Dec 2025 stood at $8.0 million (changed N/A YoY), while the FY2025 annual figure was $8.0 million, changed N/A from the prior year.
- Other Non-Current Assets was $8.0 million for Q4 2025 at Organon, down from $120.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $120.0 million in Q1 2021 to a low of $8.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | 3.18 Bn |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.00 Mn |
| Mar 31, 2021 | 120.00 Mn |
| Dec 31, 2020 | 91.00 Mn |